Skip to main content
Equibles
SCNX logo

SCNX · Scienture Holdings, Inc. · Metrics

Track SCNX — free

Use SCNX with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research SCNX.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$2.92 +0.00 (+0.04%)
Rebalance outlook locked
Going-concern doubt — cleared Aug 13, 2026

The latest filing states the doubt was alleviated.

“While these conditions initially indicated substantial doubt about the Company's ability to continue as a going concern, management believes that its plans described above alleviate that doubt for at least one year after the date these condensed consolidated financial statements are issued.”
View the 10-Q filed Aug 13, 2026
Market Cap
$4.80M
Shares
1.64M
Volume · Oct 20 7268 Avg daily vol (11 sessions) 125.38K

SCNX metrics

56 of 116 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$2.92
Market cap
$4.80M

Price action

20 metrics
Price change (1W)
-25.3%
Price change (30D)
-21.3%
Price change (3M)
—
Price change (6M)
—
Price change (YTD)
—
Price change (1Y)
—
Trailing year
Price change (5Y)
—
52-week high
—
52-week low
—
Change from 52-week high
—
Change from 52-week low
—
Annualized volatility
—
Annualized volatility (3M)
—
Beta
—
RSI (14D)
—
Price vs SMA 50
—
Price vs SMA 200
—
Avg volume (3M)
—
Relative volume
—
Average dollar volume
—

Company

3 metrics
Sector
Healthcare
Industry
Pharmaceutical Retailers
Shares outstanding
1.64M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
11.1×
reciprocal yield 9.0%
EV / EBITDA
—
EV / EBIT
—
P / sales
6.7×
reciprocal yield 14.9%
P / book
0.1
reciprocal yield 1,161.5%
FCF yield
—
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-687.7%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
3.7×
reciprocal yield 26.8%
EV / revenue historical average (5Y)
3.7×
reciprocal yield 26.8%
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
269.2%
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
2024-07-19

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2026-10-19

Profitability

9 metrics
Gross margin
87.7%
Operating margin
-9,867.9%
Trailing 12 months
Net margin
-9,618.0%
Gross profit (TTM)
$720,438
Operating profit (TTM)
−$40.07M
Net income (TTM)
−$37.95M
Trailing 12 months
Diluted EPS (TTM)
$-51.00
FCF margin
—
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
$-49.01
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
$-46.18
Operating cash flow per diluted share (TTM)
$-14.92
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
$1.94
Stock compensation per diluted share (TTM)
$2.65
Book value per share
$43.14

Growth

11 metrics
Revenue growth YoY
+215.9%
Year over year
Net income growth YoY
-557.9%
Revenue (TTM)
$821,315
Trailing 12 months
EPS growth YoY
-208.9%
Shares change YoY
+180.1%
Year over year · more shares
Revenue CAGR (3Y)
-65.2%
Revenue CAGR (5Y)
-52.1%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-59.2%
Return on assets
-43.3%
Debt / equity
0.0
Current ratio
3.0
EBITDA (TTM)
—
Free cash flow (TTM)
—
Quick ratio
3.0
Interest coverage
-13.1
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
−$3.56M
Latest balance sheet
Cash & equivalents
$8.19M
Total assets
$87.73M
Total debt
$2.00M

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$14.44M
Capital expenditures (TTM)
—
R&D (TTM)
$2.50M
SG&A (TTM)
—
Stock compensation (TTM)
$2.11M
R&D / revenue
—
Stock compensation / revenue
—

Ownership (13F)

3 metrics
13F filers
16
13F filer change QoQ
+2
Institutional ownership
4.9%

Ownership (registered funds)

1 metrics
Index-fund ownership
2.1%

Short interest

3 metrics
Short interest
3.2%
Latest settlement · 1.0 days to cover
Days to cover
1.0d
Short-squeeze score
56 / 100

Insider activity

2 metrics
Net insider buying (90D)
—
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
—
Key facts CIK 1382574 CUSIP 80880X104 Visit website Investor relations